Authors
Latest:
The IRA Impact: Navigating Its Evolving ComplexitiesAmid lingering questions and uncertainty, a look at ways pharma companies can prioritize incorporating the Inflation Reduction Act into their strategic planning process—and do it now.
Latest:
China’s 2022 NRDL ReadoutDespite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.
Latest:
The Quest to Fully Address Prescription Drug AffordabilityThe Medicare Part D cap won’t solve need for financial assistance.
Latest:
The JAKs Journey Offers Valuable Lessons for InnovatorsOpportunity remains despite regulatory and access obstacles.
Latest:
Why A New Mix of Field Skills is Crucial to Thriving in the Digital EraEvolving preferences of HCPs during the pandemic have put an emphasis on learning new skillsets for pharma reps.
Latest:
SPBMs: Impact on Accessibility & Affordability of Gene Therapies for Rare and Orphan DiseasesThe introduction of alternative payment models and specialty pharmacy benefit management (SPBM) is poised to usher in a new era of affordability for expensive gene therapies.
Latest:
The Department of Justice is Watching: Building a Data-Driven Compliance ProgramWhether your company already has a data-driven compliance program in place or is contemplating building one, Michael O'Connor and Isha Arora outline four things the DOJ is now focused on that your compliance team needs to know.
Latest:
When to Utilize Commercial OutsourcingWhen deciding on the right commercialization model, organizations must consider multiple factors, including the asset or platform they possess, the launch timing, the funding required, and staffing expertise.
Latest:
Investing for Success: Finding the Right Launch BalanceChallenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.
Latest:
A Case for Payer Engagement and Participation in Clinical ResearchCollaboration can make commercialization processes efficient and effective.
Latest:
The Teladoc-Livongo Merger: Life Science Manufacturers’ Darwinian MomentThe recent merger of Teledoc and Livongo into a $38 billion titan proves that the market sees opportunity in health tech. Could it be an inflection point in our race towards a digital-first care model, or is this an experiment ahead of its time?
Latest:
How Medical Affairs Can Contribute to Successful Drug LaunchFaster launch planning leads to greater access.
Latest:
China: The Giant Has AwokenWith a new Chinese pharma or biotech company listing on either the HKEX or STAR exchange in China almost every week, it is important consideration US pharma and biotech companies to have a focused China market strategy, writes Enoch Kariuki.
Latest:
The Consolidated Appropriations Act and PBM TransparencyNew federal law introduces significant changes in the design of pharmacy benefit plans with aims to level the playing field between PBMs and their employee healthcare benefit plan clients.
Latest:
Embracing the Hybrid Era: Leveraging Answer Engines and Generative AI to Improve the Patient and HCP ExperienceThrough the power of large language models and generative AI, pharma and biotech companies are transforming medical information delivery by offering direct, trustworthy, and accurate answers to patients and healthcare providers, significantly reducing time and frustration.
Latest:
The Cultural Deficit in the Pharma Industry in the Era of COVID-19Multicultural campaigns crafted for diverse populations are insufficiently funded and do not receive the same support as mainstream campaigns, writes Sheila Thorne. While there are plenty of people willing to partner with pharma on these campaigns, will the industry wake up to the changing world ahead?
Latest:
Behind the Creative: Let’s Hear from the CreatorsJoin Tina Fascetti, CCO of The Agency Network at MJH Life Sciences for a podcast interview with Ryan Potter, ACD Art, and Priscila Ramos, ACD Copy, from McCann Health as they share the "behind the creative" story of their Apex Award-winning consumer creative campaign for Entresto. The Apex Awards is judged by none other than the people they are aimed to connect with, the patients themselves.
Latest:
Measuring Pharma’s Trust PerformanceThe core building blocks of trust must be operationalized for pharma companies to strengthen their social contract, deliver business value, and improve patients’ quality of life.
Latest:
Advancing Healthcare Solutions: Harnessing Collaborative Business Models for OncologyUnique approaches are needed to bring solutions to fighting cancer and bacterial-resistant infections.
Latest:
Don’t Get Distracted By AI, Instead Focus on Intellectual PropertyArtificial intelligence is making it quicker to get drug candidates to the clinic, but it isn’t addressing the fundamental need to marry the right candidate and the right target to the right disease.
Latest:
How Life Sciences Can Move to Manufacturing 4.0 While Meeting Market DemandsHere are four ways life sciences organizations can quickly and cost-effectively achieve Manufacturing 4.0 benefits while still getting treatments to market.
Latest:
In DOJ Crosshairs: Rethinking Commission-Based Deals With Independent ContractorsPharma companies should review their commission-based compensation arrangements with independent contractors to address enforcement risk under the Anti-Kickback Statute, in light of recent Department of Justice enforcement.
Latest:
What Do Pharma Marketers Need to Know About Voice?Pharma marketers can use their "voice" to increase prominence in advertising.
Latest:
Why Pharma Must Invest in Key Account Management CapabilitiesThe emergence of organized customers demands investment in advanced solutions and next-generation key account management.
Latest:
Drug Manufacturers Take A Fresh Look as PAPs Continue to Hold SpotlightPatient Assistance Programs (PAPs) came out of the shadows in 2020 as several factors aligned that increased demand and awareness of these programs.
Latest:
Silver Linings of a Global Health Crisis: A New Path Forward for Pharma Media Professionalsat some point, we won’t be seeing wall-to-wall COVID coverage anymore, but stories about the fallout. How can pharmaceutical brands prepare for what’s next?
